About this role
Lycia Therapeutics is a biotechnology company using its proprietary lysosomal targeting chimera (LYTAC) platform to discover and develop best-in-class therapeutics that degrade extracellular and membrane-bound proteins. These proteins drive a wide range of difficult-to-treat diseases, including autoimmune and inflammatory conditions. Lycia was established in 2019 in collaboration with academic founder and Nobel Laureate Carolyn Bertozzi, Ph.D., professor of chemistry and HHMI investigator at Stanford University.
In June, 2026, Lycia Therapeutics completed a $75 million Series D financing to advance its pipeline of LYTAC extracellular protein degraders into the clinic. Lycia is headquartered in South San Francisco.
Visit https://lyciatx.com/ for more information.
Position Summary
Highly motivated, creative scientific leader to advance our pipeline of LYTAC degraders and help establish Lycia as the industry leader in endosomal-lysosomal degradation and delivery. This role leads both clinical pharmacology and nonclinical sciences, integrating PK/PD, exposure-response and dose-selection strategy with translational science and toxicology strategy across the pipeline. A successful candidate can effectively work cross-functionally and has a strong drug development track record of advancing programs from target discovery through IND/clinical stage.